This guide covers general consumer protection information related to GLP-1 telehealth providers. It is written by an attorney but does not constitute legal advice for your individual situation. If you have been defrauded, charged without authorization, or denied access to prescription medication you paid for, you may have legal remedies. Consult a licensed attorney in your state. GLP-1 medications require a valid prescription from a licensed healthcare provider. Nothing in this guide constitutes medical advice or a recommendation to start, stop, or change any medication.
The Current Landscape of GLP-1 Telehealth Providers
The GLP-1 telehealth market expanded at extraordinary speed following FDA approval of semaglutide and tirzepatide for obesity, and particularly after compounding pharmacies began producing alternatives to brand-name Ozempic and Wegovy. Between 2022 and 2025, dozens of operators entered the market — some with established telehealth infrastructure, others as essentially new entrants built around the GLP-1 demand spike. Providers including LifeMD, Ro Health, Eden Health, Mochi Health, TrimRx, and many smaller operators competed aggressively for patients, often through digital advertising promising rapid access to prescription GLP-1 medications at prices far below retail pharmacy costs.
The speed of that expansion exceeded the pace of regulatory oversight. Several providers are now under scrutiny or have faced operational disruptions that directly affect patient care. Mochi Health — one of the higher-profile GLP-1 telehealth operators — has faced state pharmacy board investigations related to its compounding operations. Patient communities on Reddit, X, and Facebook have documented complaints about billing practices, difficulty reaching support, prescriptions being delayed or unfilled, and providers abruptly changing service models in ways that disrupt ongoing treatment. Provider acquisitions have introduced a separate layer of instability: when a smaller telehealth company is acquired by a larger operator or private equity vehicle, the acquiring company frequently changes the service model, pricing structure, or pharmacy relationships in ways that catch existing patients off guard.
Insurance changes have added to the disruption. Cigna, which had been one of the broader insurers for GLP-1 coverage under certain employer plans, has moved to restrict or eliminate coverage for GLP-1 medications prescribed for weight loss (as distinct from type 2 diabetes, where coverage is more commonly maintained). Patients who built their access model around insurance coverage suddenly found themselves without coverage and facing out-of-pocket costs of several hundred dollars per month. Many shifted to compounded GLP-1 telehealth providers as a lower-cost alternative — which brings them directly into the landscape of provider quality variation described in this guide.
The regulatory environment itself is also evolving. The FDA's shortage designation that allowed compounding pharmacies to produce semaglutide and tirzepatide under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act was tied to documented shortage conditions. As brand-name supply has normalized, the FDA has been progressively tightening the grounds on which compounding is permitted. What was a clearly permissible avenue for a telehealth provider in 2023 or 2024 may be operating in a more contested regulatory space in 2026. Providers that built their business model on compounding access face genuine legal and operational uncertainty. Patients need to understand that the platform they are relying on for ongoing medication access may face existential regulatory pressure — and they should plan accordingly.
This guide covers general patterns and consumer protection principles. It is not an investigation of any specific company, and no company named in this guide has been found liable or adjudicated as fraudulent by any court. The complaints, investigations, and disruptions described reflect publicly reported information from patient communities, regulatory filings, and press coverage as of mid-2026. Situations evolve. Verify current status independently before making decisions about your care.
Red Flags: What to Watch For in a GLP-1 Telehealth Provider
Not all GLP-1 telehealth providers are problematic, and the existence of complaints about some operators does not mean all are operating in bad faith. But the market's rapid growth created conditions in which poorly structured or predatory operators could enter alongside legitimate ones. The following red flags are not individually definitive — some can reflect operational growing pains rather than fraud — but multiple red flags in combination warrant serious caution before subscribing or continuing with a provider.
- No identifiable licensed prescribing physician. You should be able to identify the specific licensed physician assigned to your care, verify their name, and look up their license through the state medical board. Vague references to "our medical team" without an identifiable physician are a structural warning.
- Compound dispensed without a valid prescription from a licensed provider. Any GLP-1 medication, whether brand-name or compounded, legally requires a valid prescription from a licensed healthcare provider. If you are receiving medication without a meaningful clinical interaction leading to a documented prescription, that is both legally problematic and a patient safety concern.
- Pressure to purchase multi-month supplies upfront. High-pressure tactics encouraging you to buy 3-, 6-, or 12-month supplies before you know how you respond to the medication — with limited or no refund policy — are a consumer protection red flag. Legitimate providers allow monthly subscriptions or clearly explain cancellation and refund terms before payment.
- No clear process for side effect management or provider contact. GLP-1 medications can produce significant side effects that require clinical guidance. A provider that offers no identifiable pathway for reporting side effects and reaching a medical professional is not providing adequate patient care, regardless of what its marketing materials say.
- Subscription model that auto-renews without a clinical check-in. Responsible GLP-1 prescribing requires periodic clinical reassessment. A provider that auto-bills and auto-ships medication indefinitely without any clinical re-evaluation is operating at the margin of acceptable telehealth practice.
- No refund policy if medication is defective, recalled, or ineffective. Patients who receive defective compounded medication, or medication from a pharmacy that is later recalled or found to be non-compliant, are entitled to remedies. Providers that disclaim all refund obligations categorically are structuring themselves to externalize all risk onto the patient.
- Pharmacy not identifiable or not licensed in your state. The dispensing pharmacy must be licensed to dispense in your state of residence. A provider that will not tell you which pharmacy will fill your prescription — or where to find that pharmacy's license — is not operating transparently.
- No VIPPS accreditation or NABP verification for the dispensing pharmacy. VIPPS (Verified Internet Pharmacy Practice Sites) accreditation from the National Association of Boards of Pharmacy is a credible indicator of pharmacy legitimacy. All pharmacies should be verifiable through NABP.pharmacy. A pharmacy that cannot be verified through these sources warrants additional scrutiny.
- Inability to obtain your prescription or transfer it to another pharmacy. You have a legal right to your prescription. A provider that refuses to provide you with your own prescription, or that creates structural barriers to prescription transfers, is not complying with pharmacy and medical records law.
High complaint volume alone does not prove a provider is fraudulent — large operators serving hundreds of thousands of patients will generate more complaints in absolute terms than small ones. What matters is the pattern: are complaints concentrated around specific practices (billing, prescription withholding, support unavailability), and do they reflect systemic issues rather than isolated incidents? Checking the Better Business Bureau, Reddit's r/Ozempic and r/semaglutide communities, and state AG complaint databases before selecting a provider is a reasonable due diligence step.
It is also worth distinguishing between providers that are operationally struggling and those that are operating with intent to deceive. Many GLP-1 telehealth companies expanded so rapidly that their support, pharmacy coordination, and clinical infrastructure could not keep pace. This creates patient harm — delayed prescriptions, unanswered support tickets, billing errors — even without bad intent. The distinction matters for how you respond: operational failures call for complaints and escalation; deceptive practices call for regulatory reporting and, potentially, legal action. Both situations warrant prompt action on your part to protect your access to care and your financial interests.
Section 3 — Know Your RightsPatient Rights: What You Are Entitled To
Patients using telehealth providers for GLP-1 medications have the same core rights as patients using any healthcare provider. These rights are grounded in federal and state law — HIPAA for medical records, pharmacy law for prescription access, consumer protection law for billing and subscription practices, and common law for breach of contract and fraud. Telehealth's digital-only, subscription-based structure does not eliminate these rights; it just means more patients are unaware of them.
- A copy of your prescription on request. Pharmacies and prescribing providers are legally required to provide you with a copy of any prescription written for you. This is not a courtesy; it is a legal right under federal and state pharmacy and medical practice law. A refusal to provide your prescription is a reportable violation.
- To transfer your prescription to any licensed pharmacy. You may take your prescription to any pharmacy that is licensed to fill it. A telehealth provider does not own your prescription; you do. Structural barriers to prescription transfer — such as requiring you to use a specific proprietary pharmacy under penalty of prescription termination — are legally suspect in most jurisdictions.
- Your complete medical records within 30 days of request. Under HIPAA, covered entities are required to provide you with access to your medical records within 30 days of a written request (with one possible 30-day extension). This includes your prescription history, any clinical notes from telehealth visits, lab results, and assessments. You may be charged a reasonable fee for copying, but the records cannot be withheld.
- A refund of medication costs if medication is defective or recalled. If compounded medication you received is defective — wrong concentration, contamination, improperly formulated — or if the pharmacy's products are subject to a recall, you have legal remedies. This includes refund claims directly against the provider and, potentially, the pharmacy. Document everything in writing.
- To know the identity of your prescribing physician and verify their license. You are entitled to know who is prescribing your medication. This is not optional information that providers can obscure behind brand identity. Ask for the name of your prescribing physician, their state of licensure, and their NPI (National Provider Identifier) number.
- To cancel a subscription without penalty, subject to your contract terms. Read your subscription agreement before signing up. Under many state consumer protection laws, automatic renewal provisions must be disclosed clearly and cancellation must be straightforward. If a provider is making cancellation unreasonably difficult — such as requiring phone calls to a support line that is never available — that may constitute an unfair business practice under state law.
- To report adverse events to FDA MedWatch without retaliation. You have a right to report adverse events from compounded or prescription medications to the FDA's MedWatch program at fda.gov/safety/medwatch. No provider can contractually waive your right to report to federal regulatory agencies.
- To file complaints with state and federal agencies. Your right to file complaints with your state attorney general, state pharmacy board, state medical board, FTC, and FDA cannot be waived by contract. Any provision in a telehealth agreement that purports to bar regulatory complaints is unenforceable.
One right worth emphasizing specifically: your prescription is yours. This comes up repeatedly in GLP-1 telehealth complaints, where patients report that providers claim they cannot provide a standalone prescription because the medication is dispensed only through the provider's proprietary pharmacy. This characterization is typically false and legally problematic. A prescription written by a licensed physician is a legal document; it belongs to the patient, not the telehealth platform. Some providers structure their service as a "medication management fee" that bundles the physician consultation and the pharmacy fill in a way that makes the prescription unavailable separately — but this structure does not eliminate your right to your underlying prescription. If you encounter this, put your request in writing, cite applicable state pharmacy law, and escalate to your state pharmacy board if the request is refused.
The specific mechanics of prescription rights vary by state. California, New York, and Texas, for example, have consumer protection regulations that provide specific patient protections in telehealth contexts. If you are navigating a dispute with a telehealth provider, a brief consultation with a licensed attorney in your state who handles consumer protection or healthcare law is worth the investment to understand your specific rights and remedies.
What to Do If Your Provider Disappears or Is Acquired
Provider acquisitions, closures, and service model changes are not hypothetical risks in the GLP-1 telehealth market — they are documented, recurring events. When a telehealth company is acquired by a larger operator or shuts down, patients frequently lose access to their prescribing relationship abruptly, without adequate transition planning. Acting quickly when you learn of a provider disruption maximizes your options. Waiting to see how things develop often results in losing records, prescriptions, and medications you paid for.
- Request your complete medical records and prescription history in writing immediately. Send a written request (email with read receipt creates a paper trail) citing your HIPAA right to records access within 30 days. Do this before the company's systems go offline or become inaccessible. Include your full name, date of birth, and account number, and specify that you want all clinical notes, prescriptions, lab results, and assessments.
- Request a hard copy of your active prescription if possible. Ask the provider directly to send you a copy of your current active prescription. If the provider is still operational, even under transitional management, you are entitled to this document. Having it in hand allows you to take it to any pharmacy or new telehealth provider immediately.
- Request copies of any lab work or assessments in your file. GLP-1 treatment may involve baseline labs, follow-up bloodwork, or clinical assessments. These are part of your medical record. Obtain them before they become inaccessible. They will be needed by any new provider to continue your care appropriately.
- Contact your primary care physician. Establishing continuity of care through a PCP is the most reliable safety net when a telehealth provider fails. Your PCP can review your history, continue your GLP-1 prescription if clinically appropriate, and provide a stable prescribing relationship that is not subject to market volatility. If you do not have a PCP, this disruption is a prompt to establish that relationship.
- Identify alternative GLP-1 providers before your current supply runs out. Do not wait until you are out of medication to find a new provider. Research alternatives, verify their legitimacy using the criteria in Section 6 of this guide, and have a new provider relationship in place before your current supply is exhausted. The evaluation process takes time.
- File a complaint with your state attorney general's consumer protection division if you were billed for services not rendered. If you paid for medication or services that were not delivered due to the provider's closure or acquisition-related service change, file a complaint promptly. Most state AG offices have online complaint portals. Document your payment, what was promised, and what was not delivered.
- Dispute charges with your credit card company if you paid for medication or services not received. Under the Fair Credit Billing Act, you generally have 60 days from the statement date on which the charge appeared to dispute a charge for services or goods not received. If you paid by debit card, check the error resolution rules for your bank. Credit card chargebacks are one of the most effective immediate remedies for payment disputes with companies that are unresponsive.
If your provider has been acquired rather than closed, the situation is different but still requires proactive steps. Acquisitions frequently result in changes to the service model, pricing, pharmacy relationships, and prescribing protocols. The acquiring company may not be obligated to continue your existing subscription terms, and it may change the compounding pharmacy, the medication formulation, or the clinical support model. Ask the acquiring company in writing: What happens to your existing prescription? What pharmacy will fill your medication going forward? What are the terms of your subscription under the new ownership? Can you opt out and take your prescription elsewhere?
Abrupt discontinuation of GLP-1 medications can result in rebound weight gain and metabolic effects. If your telehealth provider fails and you cannot immediately secure a new prescribing relationship, contact your primary care physician or an urgent care provider with prescribing authority to bridge your care. Do not abruptly stop GLP-1 therapy without medical guidance if it has been part of your ongoing treatment regimen. This is one reason to establish a PCP relationship even if you primarily use telehealth for GLP-1 prescribing.
Reporting: State AG and FTC Resources
Regulatory complaints are not just individual remedies — they are also how enforcement actions get triggered. FTC and state attorney general investigations into specific companies are frequently initiated or expanded based on complaint volume patterns. A single complaint may not prompt action; a consistent pattern of similar complaints from multiple consumers often does. Filing a complaint, even when you do not expect direct individual resolution, contributes to the enforcement record that regulators use when deciding whether and how to act.
The FTC's primary jurisdiction covers deceptive and unfair business practices in commerce. For GLP-1 telehealth, relevant violations include: deceptive advertising about efficacy or access; unauthorized billing; failure to deliver products or services paid for; subscription traps that make cancellation unreasonably difficult; and deceptive claims about physician oversight. File at ftc.gov/complaint. The FTC does not resolve individual complaints but uses complaint data to identify patterns for investigation.
Every state has an attorney general's office with a consumer protection division. State AG offices can investigate deceptive practices against state residents and often have authority to seek restitution for affected consumers, not just penalties for violators. Most state AG offices have online complaint portals. Find yours through naag.org (National Association of Attorneys General). State AG offices have historically been among the most effective actors in pursuing telehealth and subscription fraud.
MedWatch is the FDA's safety reporting system for adverse events from medications, including compounded medications. If you experienced a serious adverse event from a compounded GLP-1 medication — such as unexpected potency, contamination, or a reaction inconsistent with the labeled formulation — report it at fda.gov/safety/medwatch. These reports are used by the FDA's Office of Criminal Investigations and its compounding oversight unit when evaluating pharmacy compliance. Reports from multiple patients about the same pharmacy can trigger inspections.
Compounding pharmacy complaints go to the state pharmacy board in the state where the pharmacy is licensed. The National Association of Boards of Pharmacy (NABP) maintains a directory at NABP.pharmacy that allows you to identify and verify pharmacies and locate the relevant state board. Pharmacy board complaints are appropriate for: dispensing compounded medications without a valid prescription; pharmacy operating in a state without licensure; medication quality and contamination issues; and refusal to provide prescription copies.
If your complaint involves the prescribing physician — such as prescribing without an adequate clinical assessment, prescribing controlled substances or high-risk medications without appropriate oversight, or failing to respond to patient communications about adverse effects — file a complaint with the medical board in the state where the physician is licensed. Find your state medical board through the Federation of State Medical Boards at fsmb.org.
BBB complaints are not regulatory in the same sense as agency complaints, but they serve an important function: documentation. BBB complaint records are public, searchable, and factored into BBB ratings, which many consumers check before selecting providers. Filing a BBB complaint creates a documented record of your dispute and the company's response, which can be useful if you later pursue credit card disputes, state AG complaints, or legal action. Find company listings and file complaints at bbb.org.
One practical note on documentation: before filing any complaint, assemble your evidence. This means screenshots of marketing claims that were not fulfilled, copies of your subscription agreement and terms of service, payment records, email correspondence with the provider's support team, and a clear timeline of what you paid for, what you received, and when service failures occurred. Organized, documented complaints are more likely to be investigated seriously than vague descriptions of dissatisfaction. The time spent assembling documentation before filing pays dividends in every subsequent escalation step, including credit card disputes.
The FTC and state AG investigations that have been brought against digital health companies — including in the subscription services and telehealth space — have frequently been triggered by complaint volume patterns. Individual consumers who take the time to file well-documented complaints are not just seeking individual remedies; they are contributing to the enforcement record that regulators use when allocating limited investigative resources. In a market that expanded faster than oversight, complaint patterns are often the first signal regulators receive that a specific operator warrants attention.
Evaluating a New Telehealth Provider Before You Subscribe
Given the landscape described above, the question is not just whether GLP-1 telehealth is a legitimate access pathway — it is, and for many patients it provides cost-effective, convenient access to evidence-based treatment that they could not otherwise obtain — but how to select a provider that is operating legitimately and will actually deliver what it promises over time. A few concrete steps before subscribing significantly reduce the risk of the problems described in this guide.
Pre-Subscription Due Diligence Checklist
Step 1: Verify the Prescribing Physician
Before subscribing, ask the provider to identify the specific licensed physician who will be responsible for your care. Some providers will assign you a physician at intake; others operate with a pool of physicians. Either approach is potentially fine, but you should be able to identify the specific physician who actually signs your prescription. Once you have a name, verify their medical license through your state medical board's online license lookup tool. This is a free, public search that takes approximately two minutes. You are verifying that the license is current and in good standing, that the physician is licensed in your state of residence (not just in a remote state), and that there are no disciplinary actions on their record.
Step 2: Verify the Dispensing Pharmacy
Ask the provider directly: which specific compounding pharmacy will fill my prescription? A legitimate provider will be able to answer this question. With the pharmacy name and location, verify its license through NABP.pharmacy or your state pharmacy board. You are checking that the pharmacy is licensed in your state, that it is not subject to active regulatory action, and ideally that it has VIPPS accreditation or 503B outsourcing facility status, which indicates a higher level of regulatory compliance in the compounding context. If the provider cannot or will not identify the dispensing pharmacy, that is a red flag serious enough to end the evaluation.
Step 3: Read the Cancellation and Refund Policy Before Subscribing
The Terms of Service and cancellation policy are not afterthoughts. Read them before entering any payment information. Specifically: What is the cancellation process, and can it be done online without calling a phone number? What is the refund policy for unused medication, medication not shipped, or medication that causes adverse effects requiring discontinuation? Are there any fees associated with early cancellation? Are there any provisions waiving your right to dispute charges or file regulatory complaints? Any provision purporting to bar you from contacting regulatory agencies is unenforceable, but its presence in a contract tells you something about the provider's posture toward consumer rights.
Step 4: Ask Direct Questions Before Committing
A few questions worth asking explicitly, via email or chat (so you have a documented answer) before subscribing:
- Who is my specific prescribing physician, and what is their state license number?
- Which pharmacy will fill my prescription, and is it licensed to dispense in my state?
- What happens to my prescription if your service model changes or the company is acquired?
- Can I obtain a paper or PDF copy of my prescription to take to another pharmacy if needed?
- What is the process for reporting a side effect and reaching a medical professional during business hours?
- Is the medication dispensed as a compounded product, and if so, under what legal authority?
A provider that answers these questions straightforwardly and in writing is demonstrating operational transparency. A provider that deflects, provides only marketing language in response, or claims it cannot answer these questions should be approached with significant caution.
Step 5: Research Independent Patient Experiences
Before subscribing to any specific provider, spend 20 minutes reading recent posts about that provider in GLP-1 communities on Reddit (r/Ozempic, r/semaglutide, r/tirzepatide), Facebook groups, and X. Community discussions surface operational issues — support failures, shipping delays, billing problems, prescription withholding — faster than any other source. You are not looking for isolated complaints; you are looking for patterns. Complaints from the last 90 days are more informative than older ones, because providers' quality and operational status can change rapidly. Also check the Better Business Bureau and your state AG's consumer complaint database if it is publicly searchable.
One additional principle: prefer providers with established operating histories. The GLP-1 telehealth market has been a new-entrant market, with many operators that did not exist before 2022 or 2023. Newer entrants have shorter track records and less demonstrated ability to sustain service quality through market changes. A provider that has been operating since 2020 or earlier, that has published physicians on staff who can be independently verified, and that has managed through at least one market disruption without catastrophic patient impact is a qualitatively different risk than a company that launched 18 months ago and is still in rapid-growth mode. That is not a definitive bar — newer providers can be legitimate and older ones can have problems — but operating history is a meaningful input to the evaluation.
GLP-1 medications — including compounded semaglutide and tirzepatide — require a valid prescription from a licensed healthcare provider. No telehealth provider, regardless of marketing claims, can legally dispense these medications without a valid prescription. If you are evaluating a provider and the purchase pathway does not involve a licensed physician consultation and a documented prescription, do not proceed. Any provider offering to ship GLP-1 medication without a prescription is operating outside the law, and receiving such medication carries significant personal health and legal risk.
Frequently Asked Questions
Is Mochi Health under investigation?
Mochi Health has faced scrutiny from state pharmacy boards related to its compounding pharmacy operations. Pharmacy board investigations typically focus on whether compounding practices comply with state and federal standards, whether prescriptions are valid, and whether patient safety protocols are adequate. Patients who are current Mochi clients should monitor for communications from the company and consider requesting copies of their prescriptions and medical records proactively, regardless of how those proceedings resolve. This guide cannot provide legal advice about any specific ongoing proceeding, and patients with specific concerns should consult a licensed attorney in their state. Information about regulatory proceedings involving specific providers changes rapidly, and this guide reflects publicly available information as of June 2026.
Can my telehealth GLP-1 provider legally withhold my prescription?
Generally, no. You are entitled to a copy of any valid prescription written for you. Under federal and state pharmacy law, a pharmacist must provide a patient with a copy of their prescription upon request. Your prescribing provider is also obligated to provide you with your prescription upon request. If a telehealth company is refusing to release your prescription or claiming it cannot be transferred, that is a potential violation of pharmacy law and a red flag worth escalating. You can contact your state pharmacy board and state attorney general's consumer protection division to report a refusal to provide a prescription copy. Put your request in writing before filing the complaint, so you have documentation that you asked and were refused. Note that some providers structure their services in ways designed to obscure the prescription relationship; this structure does not eliminate your underlying legal rights to your prescription.
What should I do if my GLP-1 telehealth provider suddenly shuts down or is acquired?
Act immediately on several fronts. Request your complete medical records and prescription history in writing, creating a documented paper trail; request a hard copy of your current active prescription; contact your primary care physician to establish continuity of care and have the GLP-1 prescription transferred to a new provider relationship; identify alternative telehealth providers before your current supply runs out; and if you paid for services or medication not received, dispute charges with your credit card company and file a complaint with your state attorney general's consumer protection division. If the company has been acquired rather than closed, contact the acquiring company in writing to ask what the transition plan is for existing patients and prescriptions, and whether your current prescription terms are honored under new ownership. Do not abruptly stop GLP-1 therapy without medical guidance if it has been part of your ongoing treatment.
My insurance (Cigna) cancelled my GLP-1 coverage. What are my options?
Insurance coverage cancellations for GLP-1 medications have been common, particularly at employers that have revisited the cost of GLP-1 coverage in their benefit plans. Cigna and other large insurers have moved to restrict or eliminate coverage for GLP-1 medications prescribed for weight loss (as distinct from type 2 diabetes, where coverage is more commonly maintained). If your coverage was cancelled, your options include: appealing the cancellation through your plan's internal appeal process, which typically requires a written appeal within 180 days of the denial; requesting an exception based on documented comorbidities or prior authorization supported by your physician; exploring compounded semaglutide or tirzepatide through a telehealth provider, which does not go through insurance and currently costs significantly less than retail brand-name pricing; asking your prescriber about manufacturer patient assistance programs for Ozempic, Wegovy, Mounjaro, or Zepbound; and reviewing the specific terms of your employer health plan, which may include a grievance procedure for coverage decisions. The coverage landscape is evolving rapidly and varies significantly by employer plan design and your state of residence.
How do I verify that a telehealth GLP-1 provider is legitimate?
Start with three core verifications before subscribing. First, identify the specific licensed physician who will prescribe for you and verify their medical license through your state medical board's online lookup tool — check that it is current, in good standing, and that there are no disciplinary actions. Second, identify the compounding pharmacy that will fill your prescription and verify it is licensed in your state through NABP.pharmacy or your state pharmacy board. Third, read the cancellation and refund policy carefully before entering any payment information. Beyond these three steps: research the provider in GLP-1 patient communities for recent complaint patterns; check the Better Business Bureau; ask the provider in writing to identify your prescribing physician and dispensing pharmacy; and prefer providers with multi-year operating histories over new market entrants. A provider that answers direct questions about physician identity and pharmacy licensing clearly and in writing is demonstrating the transparency that legitimate operators should be willing to provide.
Can compounded semaglutide or tirzepatide still be legally dispensed in 2026?
As of June 2026, the FDA has declared national shortages of both semaglutide and tirzepatide resolved. That resolution ended the primary legal basis — the drug shortage exception — that permitted compounding pharmacies to mass-produce GLP-1 medications. Large-scale 503B outsourcing facility compounding of these drugs no longer has a legal basis. Mass-market compounded GLP-1 programs at platforms like Hims, Ro, and LifeMD are ending as a result. Limited patient-specific compounding by 503A pharmacies may remain available in narrow cases where a prescriber documents an individualized medical need that commercially available products cannot address (such as a documented excipient allergy) — but general commercial compounded GLP-1 programs do not meet this standard. If you have a specific question about whether patient-specific compounding might apply to your situation, consult your prescriber and a licensed attorney with healthcare regulatory experience. See our full guide: Your Compounded GLP-1 Program Is Ending: What to Do Now.